In the United States<unk>  is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. In the European Union it is indicated in adults aged 18 years and older with type 2 diabetes mellitus: * to improve glycemic control when metformin with or without sulphonylurea (SU) and either<unk>  or<unk>  does not provide adequate glycemic control. * when already being treated with<unk>  and<unk> .
Dapagliflozin/saxagliptin
Canagliflozin/metformin
Empagliflozin/linagliptin
Empagliflozin/metformin
Insulin degludec/liraglutide
Pioglitazone/metformin
Pioglitazone/glimepiride
Dapagliflozin/metformin